Macquarie cuts Trip.com stock rating on regulatory uncertainty

Macquarie downgraded Trip.com Group to Neutral from Outperform and cut its price target to $44.30 from $70.90, citing uncertainty around regulatory probes and softer near-term monetization visibility. Trip.com’s Q1 2026 revenue rose 17% year over year and beat expectations, but adjusted net profit missed estimates and management guided Q2 revenue growth to just 3% to 8% amid weaker long-haul demand and regulatory-driven adjustments. The stock trades at $40.49, near its 52-week low of $38.04 and down 44% over the past six months.

Analysis

The key takeaway is not the revenue miss; it is the collapse in earnings visibility. When a platform business with still-healthy booking momentum gets de-rated on guidance and regulatory overhang, the market is effectively saying monetization is no longer the cleanest lever — that usually compresses multiple before it compresses top-line estimates. The second-order effect is that incremental demand strength may accrue more to inventory owners and lower-take-rate channels than to the OTA itself, especially if regulatory pressure continues to cap value-added services and ancillary monetization.

The setup likely worsens before it improves because the next catalyst is not another quarter of growth, but whether management can demonstrate stabilization in travel mix and pricing elasticity. If oil-driven airfare inflation persists, long-haul demand should remain soft for 1-2 quarters, which matters more than the reported booking growth because it can shift mix toward lower-margin domestic volume. That combination can keep estimate revisions negative even if headline bookings stay resilient.

The contrarian read is that the drawdown may be partially overdone if investors are pricing a permanent impairment rather than a temporary de-rating. The balance sheet gives management time, and the stock is now in a zone where any sign of regulatory clarity or easing airfare pressure could trigger a sharp short-covering rally. But until guidance inflects, the setup is still one where rallies are more likely sold than chased.

Key Decisions for Investors

• Avoid initiating fresh long TCOM here; wait for evidence of guidance stabilization or regulatory clarity over the next 1-2 quarters before treating it as a value entry.
• For event-driven accounts, buy short-dated TCOM put spreads into any bounce toward the low-40s; thesis is that estimate revisions and guidance uncertainty can keep pressure on the stock over the next 4-8 weeks.
• Relative value: long CTRP/expedia-adjacent beneficiaries with cleaner monetization visibility versus short TCOM if you want to express that travel demand is not the issue — take-rate and regulation are.
• If you want a contrarian trade, consider a small tactical long in TCOM only on a confirmed regulatory headline or upward revision in Q2 demand indicators; use a tight stop below the recent low because the stock can re-rate quickly on any visibility improvement.